Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors [2] - The lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [2] - Other candidates in development include Atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with a focus on orally delivered, small molecule, new chemical entities [2] Upcoming Event - Crinetics Pharmaceuticals will host an in-person and virtual R&D Day in New York on June 26, 2025, from 9:00 AM to 12:00 PM ET [1] - The event will provide updates on early-stage pipeline assets, next steps, and portfolio strategy aimed at driving long-term value [1] - A live question-and-answer session will follow the formal presentations during the event [1]